Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Share & Trends Analysis Report, By Drug Class (Beta Adrenergic Blocking Agents, Anticoagulants, Antiarrhythmic Agents, Calcium Channel Blockers, and Others) and Forecast, 2020-2026
The global hypertrophic cardiomyopathy (HCM) therapeutics market is expected to witness sluggish growth during the forecast period. Rising awareness regarding heart diseases is contributing to market growth. The government initiatives to increase awareness regarding CVD health is leading to an increasing diagnosis and treatment of the condition. There are several awareness programs launched to make aware people regarding prevention and control of CVD. For instance, in 2004, the American Heart Association launched an international awareness campaign, referred to as Go Red for Women campaign, for the prevention, diagnosis and control of CVD in women. These kinds of initiatives enable to increase awareness about the conditions, leading to an early diagnosis of CVD. This, in turn, is expected to drive the demand for HCM medications to decrease heart rate that enables the heart to pump blood better. However, emerging demand for cardiac surgeries is primarily restricting the growth of the market.
Geographically, Asia-Pacific is estimated to witness significant growth during the forecast period owing to the increasing prevalence of CVD and increasing government focus towards prevention, diagnosis, and treatment of the condition. HCM is the most common inherited cardiac disease that has been witnessing increasing prevalence in Asia-Pacific countries, including China and India. This, in turn, will encourage the demand for medications to control symptoms and prevent sudden death.
Key players in the market include AstraZeneca plc, ANI Pharmaceuticals, Inc., MyoKardia, Inc., Bayer AG, and Sanofi S.A. ANI Pharmaceuticals offers InnoPran XL, Inderal LA, and Inderal XL, that are used for the treatment of HCM. InnoPran XL is a class of medications referred to as beta-adrenergic blocker, designed to treat hypertension, to lower blood pressure. The reduction in blood pressure minimizes the risk of fatal and non-fatal CVD events, particularly myocardial infarction and strokes. Further, MyoKardia, Inc., mavacamten is in Phase II for the treatment of obstructive HCM.
Research Methodology
The market study of the global HCM therapeutics market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Global HCM Therapeutics Market Research and Analysis by Drug Class
The Report Covers
The global hypertrophic cardiomyopathy (HCM) therapeutics market is expected to witness sluggish growth during the forecast period. Rising awareness regarding heart diseases is contributing to market growth. The government initiatives to increase awareness regarding CVD health is leading to an increasing diagnosis and treatment of the condition. There are several awareness programs launched to make aware people regarding prevention and control of CVD. For instance, in 2004, the American Heart Association launched an international awareness campaign, referred to as Go Red for Women campaign, for the prevention, diagnosis and control of CVD in women. These kinds of initiatives enable to increase awareness about the conditions, leading to an early diagnosis of CVD. This, in turn, is expected to drive the demand for HCM medications to decrease heart rate that enables the heart to pump blood better. However, emerging demand for cardiac surgeries is primarily restricting the growth of the market.
Geographically, Asia-Pacific is estimated to witness significant growth during the forecast period owing to the increasing prevalence of CVD and increasing government focus towards prevention, diagnosis, and treatment of the condition. HCM is the most common inherited cardiac disease that has been witnessing increasing prevalence in Asia-Pacific countries, including China and India. This, in turn, will encourage the demand for medications to control symptoms and prevent sudden death.
Key players in the market include AstraZeneca plc, ANI Pharmaceuticals, Inc., MyoKardia, Inc., Bayer AG, and Sanofi S.A. ANI Pharmaceuticals offers InnoPran XL, Inderal LA, and Inderal XL, that are used for the treatment of HCM. InnoPran XL is a class of medications referred to as beta-adrenergic blocker, designed to treat hypertension, to lower blood pressure. The reduction in blood pressure minimizes the risk of fatal and non-fatal CVD events, particularly myocardial infarction and strokes. Further, MyoKardia, Inc., mavacamten is in Phase II for the treatment of obstructive HCM.
Research Methodology
The market study of the global HCM therapeutics market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Global HCM Therapeutics Market Research and Analysis by Drug Class
The Report Covers
- Comprehensive research methodology of the global HCM therapeutics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global HCM therapeutics market.
- Insights about market determinants, which are stimulating the global HCM therapeutics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- A. Menarini Farmaceutica Internazionale srl
- ANI Pharmaceuticals, Inc.
- AstraZeneca plc
- Bayer AG
- Bristol Myers Squibb Co.
- Cipla Ltd.
- General Electric Co.
- Gilead Sciences, Inc.
- Lannett Co., Inc.
- Merck & Co., Inc.
- Mylan N.V.
- MyoKardia, Inc.
- Novartis International AG
- Pfizer Inc.
- Sanofi S.A.
